Incorporating Genomics into Breast Cancer Clinical Trials and Care
暂无分享,去创建一个
[1] J. Baselga,et al. Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer , 2013, Clinical Cancer Research.
[2] J. Reis-Filho,et al. Tackling the Diversity of Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.
[3] Ron Bose,et al. Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data , 2013, PloS one.
[4] Levi A Garraway,et al. Precision oncology: an overview. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Ellis,et al. Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models , 2013, Molecular Cancer Therapeutics.
[7] G. Mills,et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. , 2013 .
[8] I. Bièche,et al. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01). , 2013 .
[9] M. Piccart,et al. 42O_PRASSESSMENT OF GENETIC ALTERATIONS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FROM THE BOLERO-2 TRIAL BY NEXT-GENERATION SEQUENCING , 2013 .
[10] James X. Sun,et al. Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations , 2013, Clinical Cancer Research.
[11] David E. Housman,et al. Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines , 2013, PloS one.
[12] Evan O. Paull,et al. Molecular Pathways: Extracting Medical Knowledge from High-Throughput Genomic Data , 2013, Clinical Cancer Research.
[13] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[14] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[15] Funda Meric-Bernstam,et al. Overcoming implementation challenges of personalized cancer therapy , 2012, Nature Reviews Clinical Oncology.
[16] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[17] E. Mardis,et al. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.
[18] Daniel F Hayes,et al. Defining the benefits of neoadjuvant chemotherapy for breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[20] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[21] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[22] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[23] Ben H. Park,et al. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.
[24] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[25] Mark T. W. Ebbert,et al. Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial , 2012, Clinical Cancer Research.
[26] Jun Liu,et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Karen Page,et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. , 2012, Genome research.
[28] G. Giaccone,et al. Drug Development: Portals of Discovery , 2012, Clinical Cancer Research.
[29] J. Olson,et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[31] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[32] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[33] A. Vincent-Salomon,et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] P. Dietrich,et al. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] J. Rothberg,et al. Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.
[36] Thomas LaFramboise,et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.
[37] P. Ellis,et al. Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.
[38] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[39] C R King,et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.
[40] Karen Margolis,et al. Disclosure of Potential Conflicts of Interest , 2014 .
[41] C. Perou,et al. The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.
[42] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .